CIK 1738053
Long positions in SEC Section 13(f) securities (US-listed stocks, ADRs and ETFs), largest first · Δ vs 2019-Q3. A lagged quarterly snapshot (filed ≤45 days after quarter-end); excludes shorts, options, cash, and shares listed only on non-US exchanges — foreign companies held via a US listing or ADR (e.g. Alibaba, TSMC) ARE included.
As filed = each book applied at its quarter-end (what the reported book did) · As copyable = applied at its statutory 45-day filing deadline (what a 13F follower could have earned).
Computing…
Hypothetical modeled performance constructed with hindsight — not actual results, and not indicative of future results. See the Disclaimer.
| Industry group | Weight | Names |
|---|---|---|
| Unclassified | 49.72% | 12 |
| Pharmaceuticals & Biotechnology | 45.74% | 5 |
| Life Sciences Tools & Services | 4.54% | 1 |
| # | Ticker | Name | Sector | Weight |
|---|---|---|---|---|
| 1 | AXSM | Axsome Therapeutics, Inc. | Health Care | 31.77% |
| 2 | CONSTELLATION PHARMACEUTICALS INC. | Unclassified | 23.54% | |
| 3 | MIST | Milestone Pharmaceuticals Inc. | Health Care | 6.57% |
| 4 | RLMD | RELMADA THERAPEUTICS, INC. | Health Care | 5.95% |
| 5 | 89BIO INC | Unclassified | 5.00% | |
| 6 | TXG | 10x Genomics, Inc. | Health Care | 4.54% |
| 7 | FORTY SEVEN INC | Unclassified | 4.04% | |
| 8 | INTRA-CELLULAR THERAPIES INC | Unclassified | 3.92% | |
| 9 | IVERIC BIO INC | Unclassified | 2.90% | |
| 10 | KALVISTA PHARMACEUTICALS INC | Unclassified | 2.19% |
6/18 names classified · sector 50.3% of weight · industry 50.3% · mkt cap 50.3%; unclassified names shown, never dropped.
Sector is classified on each name's CURRENT fundamentals, not point-in-time — apparent sector drift can reflect the market re-rating a holding, not a manager trade. 13F is a lagged quarterly snapshot of long positions in US-listed securities only — foreign companies held via a US listing or ADR ARE included, but shares listed only on non-US exchanges (plus shorts, options and cash) are not. Latest quarter: 50.3% of the book is sector-classified (unclassified names shown, never dropped).
Only 0% of book weight classified — the grid is NOT representative of the whole book.
Classified: 0.0% of book weight (0/7 names) · unclassified 100.0%: , AXSM, MIST, RLMD, TXG, NXTC, PTGX. Size: cap 70/20/10 bands; style: value/growth composite on our own metrics — not Morningstar's model.
No contribution data for this period.
| # | Security | Shares | Value | Weight | Δ QoQ |
|---|---|---|---|---|---|
| 1 | AXSMAXSOME THERAPEUTICS INC. | 1,547,994 | $160M | 31.8% | TRIM −4% |
| 2 | CONSTELLATION PHARMACEUTICALS INC. | 2,516,242 | $119M | 23.5% | ADD 3674% |
| 3 | MISTMILESTONE PHARMACEUTICALS IN | 2,066,529 | $33M | 6.6% | HOLD |
| 4 | RLMDRELMADA THERAPEUTICS INC | 767,938 | $30M | 5.9% | NEW |
| 5 | 89BIO INC | 958,765 | $25M | 5.0% | NEW |
| 6 | TXG10X GENOMICS INC | 300,000 | $23M | 4.5% | HOLD |
| 7 | FORTY SEVEN INC | 516,381 | $20M | 4.0% | NEW |
| 8 | INTRA-CELLULAR THERAPIES INC | 575,000 | $20M | 3.9% | NEW |
| 9 | IVERIC BIO INC | 1,699,797 | $15M | 2.9% | NEW |
| 10 | KALVISTA PHARMACEUTICALS INC | 619,905 | $11M | 2.2% | TRIM −3% |
| 11 | Adverum Biotechnologies, Inc. | 946,234 | $11M | 2.2% | NEW |
| 12 | MARINUS PHARMACEUTICALS INC | 5,016,164 | $11M | 2.2% | ADD 99% |
| 13 | MERSANA THERAPEUTICS INC COM | 1,561,389 | $9M | 1.8% | NEW |
| 14 | MYOVANT SCIENCES LTD | 455,255 | $7M | 1.4% | NEW |
| 15 | NXTCNEXTCURE INC | 119,693 | $7M | 1.3% | NEW |
| 16 | OBSEVA SA | 810,264 | $3M | 0.6% | TRIM −30% |
| 17 | PTGXPROTAGONIST THERAPEUTICS INC | 80,929 | $571,000 | 0.1% | TRIM −92% |
| 18 | BELLEROPHON THERAPEUTICS INC | 383,955 | $134,000 | 0.0% | TRIM −84% |
Where this firm's principals came from and which firms its alumni went on to found.
